Page Banner
Mayo Clinic Laboratories > BioPharma Diagnostics > Testing > Hematology

HEMATOLOGY

BROAD-SPECTRUM TESTING FOR ACTIONABLE ANSWERS

A BioPharma Diagnostics engagement offers partners access to Mayo Clinic Laboratories’ robust library of hematology evaluations. Our extensive testing menu features diagnostic, prognostic, and monitoring assays across the spectrum of hematological disorders. From state-of-the-art MALDI-TOF mass spectrometry (Mayo Clinic MASSFIX) evaluations for the detection of monoclonal protein disorders, to comprehensive fluorescence in-situ hybridization (FISH) panels for personalized insights on lymphoma and myeloid neoplasms, our assays offer partners the tools needed to expedite clinical trial and drug development solutions.

Mayo Clinic Laboratories’ hematology testing laboratories are led by board-certified hematologists and hematopathologists who focus on molecular diagnostics and prognostics of hematologic disorders. Our expert-backed tests are designed to improve outcomes, increase efficiency, and decrease costs.

To learn more about our testing, view our biopharma-specific test catalog and full test catalog.

Test menu

Full suite of hematology testing Full suite of hematology testing
Full suite of hematology testing

Our comprehensive test menu has been created to aid in diagnosis and treatment selection across the full spectrum of hematologic disorders. We have developed and validated practice-based, data-driven algorithms that improve patient care, increase efficiency, and reduce costs. Our hematology experts continuously drive innovation in laboratory testing, developing new approaches and using new technology to address patient needs they see every day in clinical practice.

Acute leukemias Acute leukemias
Acute leukemias

Many myeloid neoplasms lack a clonal bone marrow cytogenetic finding at diagnosis (normal karyotype) but can be better characterized with the aid of a comprehensive gene mutation profile.

Amyloidosis Amyloidosis
Amyloidosis

Learn about our personalized approach to amyloidosis testing and how our amyloid protein identification methodology is considered the gold standard. 

Benign disorders Benign disorders
Benign disorders

Our Metabolic Hematology Laboratory is dedicated to providing accurate diagnoses and clinical interpretations for patients. For hematologists whose patients require only a single test, many components of our specialized can be ordered individually.

Coagulation disorders Coagulation disorders
Coagulation disorders

Our Special Coagulation Laboratory has been at the forefront of patient-centered and value-based diagnostic laboratory testing, research, and patient management for nearly 90 years. The laboratory offers a broad repertoire of coagulation tests covering a wide spectrum of bleeding, thrombosing, and platelet disorders.

Lymphoid disorders Lymphoid disorders
Lymphoid disorders

To assist clinicians with lymphoma diagnosis, Mayo Clinic has a highly experienced, nine-member hematopathology section focusing on lymphoma diagnosis, which diagnoses more than 3,000 lymphoma cases per year.

Myeloid neoplasms Myeloid neoplasms
Myeloid neoplasms

Our leukemia test menu includes flow cytometry, chromosome, FISH, and molecular testing. We provide accurate results and expert interpretation from a highly focused team of laboratory specialists.

Comprehensive disease testing

A BioPharma Diagnostics collaboration enables access to the hematological disease testing capabilities of Mayo Clinic Laboratories, including:

  • Acute leukemias
  • Amyloidosis
  • Benign disorders
  • Coagulation disorders
  • Lymphoid disorders
  • Myeloma
News and updates

The latest

Distinguished lineup of speakers slated for 2026 Classical Hematology Conference featured image
Distinguished lineup of speakers slated for 2026 Classical Hematology Conference

Join us at the 2026 Mayo Clinic Classical Hematology Conference: Nonmalignant Hematology and Bleeding and Thrombotic Disorders, where innovation, collaboration, and expertise come together to advance the field of hematology.

Learn more
Myeloproliferative Neoplasm: Morphology, Molecular Updates and Cost-Effective Test Utilization

The diagnosis of Myeloproliferative Neoplasm (MPN) must include an integrated approach and combine the clinical findings with laboratory results. In our latest “Hot Topic,” Rong He, M.D., discusses the subclassification of MPNs and the use of JAK2, CALR, and MPL mutational analysis in diagnosis and prognosis.

Myeloid Blast and Maturation Assessment by Flow Cytometry (“MDS Flow”)

Flow cytometric immunophenotyping method can be useful in assessing myeloid dysmaturation. In this “Hot Topic,” Dragon Jevremovic, M.D., Ph.D., describes a new flow cytometric test to detect aberrant patterns of expression in the diagnosis of myelodysplastic syndrome.